ReviewRheumatology international2025
Successful treatment of Kimura disease with Mycophenolate Mofetil: a report of two cases and review of the literature.
Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kimura Disease (KD) is a rare, chronic inflammatory disease that manifests as subcutaneous tissue swelling, often accompanied by lymphadenopathy, peripheral eosinophilia, and elevated serum IgE levels. Reported treatment options include surgery, systemic corticosteroids, and immunosuppressives. We present two patients with symptomatic KD successfully treated with Mycophenolate Mofetil (MMF). The first case is a 65-year-old Chinese man who presented with erythematous papular lesions on the neck and arms, severe Raynaud’s phenomenon, cervical lymphadenopathy, and peripheral eosinophilia. He was treated with a combination of MMF and prednisone, with resolution of his skin lesions, lymphadenopathy, and eosinophilia, and he was able to decrease the dose of prednisone. The second case is a 29-year-old Chinese female who presented with a history of membranous nephropathy, epithelioid hemangiomas of the fingers, diffuse lymphadenopathy, and peripheral eosinophilia. She was initially started on tacrolimus and prednisone with inadequate response. MMF was later added to the treatment regime, which resulted in improvement in the lymphadenopathy, and resolution of her proteinuria and peripheral eosinophilia. These two cases add to existing literature that MMF is an effective and well tolerated therapy in this very rare condition.
Indexed as
Identifiers
40924180What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.